Literature DB >> 36074157

First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours.

Isabella Silins1, Anders Sundin2, Mark Lubberink2, Lleah O'Sullivan2, Mark Gurnell3, Franklin Aigbirhio4, Morris Brown5, Anders Wall2, Tobias Åkerström2, Sara Roslin6, Per Hellman2, Gunnar Antoni6.   

Abstract

PURPOSE: [11C]Metomidate positron emission tomography (PET) is currently used for staging of adrenocortical carcinoma and for lateralization in primary aldosteronism (PA). Due to the short half-life of carbon-11 and a high non-specific liver uptake of [11C]metomidate there is a need for improved adrenal imaging methods. In a previous pre-clinical study para-chloro-2-[18F]fluoroethyletomidate has been proven to be a specific adrenal tracer. The objective is to perform a first evaluation of para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-PET/CT) in patients with adrenal tumours and healthy volunteers.
METHODS: Fifteen patients underwent [18F]CETO-PET/CT. Five healthy volunteers were recruited for test-retest analysis and three out of the five underwent additional [15O]water PET/CT to measure adrenal blood flow. Arterial blood sampling and tracer metabolite analysis was performed. The kinetics of [18F]CETO were assessed and simplified quantitative methods were validated by comparison to outcome measures of tracer kinetic analysis.
RESULTS: Uptake of [18F]CETO was low in the liver and high in adrenals. Initial metabolization was rapid, followed by a plateau. The kinetics of [18F]CETO in healthy adrenals and all adrenal pathologies, except for adrenocortical carcinoma, were best described by an irreversible single-tissue compartment model. Standardized uptake values (SUV) correlated well with the uptake rate constant K1. Both K1 and SUV were highly correlated to adrenal blood flow in healthy controls. Repeatability coefficients of K1, SUV65-70, and SUV120 were 25, 22, and 17%.
CONCLUSIONS: High adrenal uptake combined with a low unspecific liver uptake suggests that 18F]CETO is a suitable tracer for adrenal imaging. Adrenal SUV, based on a whole-body scan at 1 h p.i., correlated well with the net uptake rate Ki. TRIAL REGISTRATION: ClinicalTrials.gov , NCT05361083 Retrospectively registered 29 April 2022. at,  https://clinicaltrials.gov/ct2/show/NCT05361083.
© 2022. The Author(s).

Entities:  

Keywords:  Adrenal tracer; Positron emission tomography; [18F]CETO

Year:  2022        PMID: 36074157     DOI: 10.1007/s00259-022-05957-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  3 in total

1.  Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures.

Authors:  Hugo Jakobsson; Katerina Farmaki; Augustinas Sakinis; Olof Ehn; Gudmundur Johannsson; Oskar Ragnarsson
Journal:  Diagn Interv Radiol       Date:  2018 Mar-Apr       Impact factor: 2.630

2.  In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors.

Authors:  M Bergström; T A Bonasera; L Lu; E Bergström; C Backlin; C Juhlin; B Långström
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

3.  Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism.

Authors:  G P Rossi; M Chiesura-Corona; A Tregnaghi; L Zanin; R Perale; S Soattin; M R Pelizzo; G P Feltrin; A C Pessina
Journal:  J Hum Hypertens       Date:  1993-08       Impact factor: 3.012

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.